Cizzle Biotechnology (LON:CIZ) has crossed a major commercial threshold, with its CIZ1B lung cancer blood test now cleared for clinical use in the United States. Executive Chairman Dr Allan Syms explains why this shifts the company from development into revenue generation, how the test differs from DNA-based cancer screening, and where the next licensing opportunities could emerge as Cizzle targets wider international adoption.
Key Moments
00:13 — CIZ1B test achieves CLIA accreditation in the US
00:32 — Dr Allan Syms calls it a “stellar day” for the company
01:23 — First US patients can now be tested for the CIZ1B biomarker
02:31 — From development phase to commercial use
02:46 — How investors should view the royalty pathway
03:54 — Commercial test sales expected to drive future royalties
04:20 — Why CIZ1B differs from DNA-based cancer screening
05:40 — The “sponge” effect that could help detect very small tumours
07:08 — Licensing model and international expansion strategy
08:26 — UK, NHS and global markets in focus
09:46 — Asia-Pacific, Europe, Middle East and Latin America opportunities
10:08 — What shareholders should watch for next
Cizzle Biotechnology is a UK biotechnology and clinical diagnostics company developing and licensing blood-based diagnostic technology, with an initial focus on the early detection of lung cancer using the CIZ1B biomarker.
